Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
AssigneeLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
InventorsVirender K. Rehan, John S. Torday
Life of this patent
Estimating the term…
Abstract
This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and/or reverse the injury caused by nicotine.
Claims15
A method of reducing, eliminating, and/or reversing pulmonary tissue damage characterized by smoke-induced pulmonary alveolar trans-differentiation of lipofibroblasts to myofibroblasts in utero in a developing fetus carried by a pregnant mammal, said method comprising administering a PPAR gamma (PPARγ) agonist to said pregnant mammal in an amount sufficient to reduce, eliminate, or reverse said transdifferentiation.
Dependencies are inferred from the claim text.